Molecular engineering of antibodies for therapeutic and diagnostic purposes

During the past ten years, monoclonal antibodies (mAbs) have taken center stage in the field of targeted therapy and diagnosis. This increased interest in mAbs is due to their binding accuracy (affinity and specificity) together with the original molecular and structural rules that govern interactio...

Full description

Saved in:
Bibliographic Details
Published in:mAbs 2012-07, Vol.4 (4), p.445-457
Main Authors: Ducancel, Frédéric, Muller, Bruno H.
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - genetics
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
antibody fragments
Antibody Specificity - immunology
Binding
Biology
Bioscience
Calcium
Cancer
Cell
Clinical Trials as Topic
Cycle
display
Drug Approval
Drug Design
Engineering
Humans
in vitro evolution
Landes
mutagenesis
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplasms - immunology
Organogenesis
Protein Engineering - methods
Protein Engineering - trends
Proteins
recombinant antibody
Review
therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the past ten years, monoclonal antibodies (mAbs) have taken center stage in the field of targeted therapy and diagnosis. This increased interest in mAbs is due to their binding accuracy (affinity and specificity) together with the original molecular and structural rules that govern interactions with their cognate antigen. In addition, the effector properties of antibodies constitute a second major advantage associated with their clinical use. The development of molecular and structural engineering and more recently of in vitro evolution of antibodies has opened up new perspectives in the de novo design of antibodies more adapted to clinical and diagnostic use. Thus, efforts are regularly made by researchers to improve or modulate antibody recognition properties, to adapt their pharmacokinetics, engineer their stability, and control their immunogenicity. This review presents the latest molecular engineering results on mAbs with therapeutic and diagnostic applications.
ISSN:1942-0862
1942-0870
DOI:10.4161/mabs.20776